Triple-negative breast cancer, or TNBC, gets its name from the absence of the three molecular targets—estrogen receptors, progesterone receptors, and HER2—that drive most other breast cancers and that have enabled effective drugs for them. Without these handles, clinicians are left with chemotherapy, and outcomes remain grim: heightened invasiveness, frequent recurrence, and poor five-year survival. Because no currently approved targeted therapy exists for TNBC, finding a vulnerability that is specific to these tumors has been a central goal of cancer research for more than a decade. The new study attacks that problem from an unusual angle: not the genome, but the phosphoproteome—the vast catalog of phosphate tags attached to proteins that switch cellular machinery on and off.

The team began with deep-coverage phosphoproteomic profiling of trace clinical specimens collected across breast cancer subtypes. This ultra-sensitive approach allowed them to compare the phosphorylation patterns of proteins in tumor tissue samples so small that conventional proteomics would fail. Out of thousands of phosphorylation events, one stood out: a phosphate group attached to serine 39, a single amino acid position on the enzyme aldolase A, or ALDOA. The modification appeared consistently in TNBC specimens but not in the other breast cancer subtypes, marking it as a candidate signature of the disease. Tissue microarray analysis of larger patient cohorts then confirmed that ALDOA S39 phosphorylation was enriched in triple-negative tumors, strengthening the link between this molecular mark and the most dangerous form of breast cancer.

ALDOA is a workhorse of glycolysis, the metabolic pathway that breaks down glucose into energy and building blocks. Cancer cells famously favor glycolysis even in the presence of oxygen—the Warburg effect—because the pathway supplies both ATP and the raw materials needed for rapid cell division. The researchers wanted to know precisely how the S39 phosphate tag changes ALDOA’s behavior. Through a series of biochemical assays, they found that the phosphorylation does not alter ALDOA’s enzymatic activity directly. Instead, it changes the protein’s fate inside the cell. Unphosphorylated ALDOA is normally flagged by TRIM25, an E3 ubiquitin ligase that attaches ubiquitin chains to proteins, sentencing them to destruction by the proteasome, the cell’s waste-disposal system. But when serine 39 is phosphorylated, this ubiquitination is attenuated. The proteasome can no longer efficiently degrade ALDOA, so the enzyme accumulates to abnormally high levels.

The consequences of this stabilization are exactly what a tumor wants. Using quantitative measurements of glucose metabolism, the team showed that cells carrying phosphorylated ALDOA took up more glucose, secreted more lactate, and produced more ATP than their counterparts. In other words, the single phosphate tag acts as a metabolic master switch, cranking up glycolytic flux and endowing TNBC cells with the energy and biosynthetic capacity they need to proliferate, invade, and metastasize. When the researchers engineered cancer cells to express an ALDOA variant that could not be phosphorylated at serine 39, glycolysis dropped and tumor growth slowed, while a phosphomimetic variant had the opposite effect. The causal chain—from phosphorylation to protein stabilization to metabolic reprogramming to malignancy—was now complete on paper.

One question remained: which kinase was attaching the phosphate in the first place? To answer it, the team turned to TurboID proximity labeling combined with mass spectrometry, a technique that biotinylates proteins in the immediate vicinity of a target so they can be identified, alongside classical co-immunoprecipitation experiments. The search converged on MINK1, a kinase belonging to the germinal center kinase family that had not previously been implicated in breast cancer metabolism. The experiments confirmed that MINK1 physically interacts with ALDOA and directly phosphorylates serine 39. In TNBC cells, MINK1 activity tracked with ALDOA stability and glycolytic output, positioning MINK1 at the top of the newly discovered signaling axis.

The translational payoff came when the researchers tested KY-05009, a selective small-molecule inhibitor of MINK1 that had been developed for other purposes. In cell culture, the drug destabilized ALDOA, restored TRIM25-mediated degradation, and choked off glycolysis. The team then escalated to increasingly realistic preclinical models: cell line-derived xenografts, in which human cancer cells are implanted in mice; patient-derived organoids, miniature tumors grown from surgically obtained patient tissue that preserve the original tumor’s biology; and patient-derived orthotopic xenografts, in which patient tissue is implanted into the mammary fat pad of mice to recapitulate the tumor’s native environment. Across all of these platforms, KY-05009 suppressed tumor growth and, importantly, reduced metastasis—the process responsible for most TNBC deaths.

The significance of this work lies in both its mechanism and its strategy. Mechanistically, it reveals a complete regulatory circuit—a kinase, a phosphorylation site, an E3 ligase, and a metabolic enzyme—that had never been assembled before. Strategically, it validates the idea that proteomics of trace clinical samples can uncover disease-specific molecular events that genomics alone would miss. Phosphorylation is a reversible, drug-accessible modification, and kinases have historically been among the most successful drug targets in oncology. By nominating MINK1 as the upstream driver of TNBC’s metabolic reprogramming, the study converts a basic biochemical discovery into a therapeutic hypothesis that can be tested with tools that already exist.

There are important caveats. The findings rest on preclinical models, and the journey from xenografts and organoids to human clinical trials is long and uncertain. KY-05009 itself would need extensive safety, pharmacokinetic, and dosing studies before it could be evaluated in patients, and the field has seen many promising kinase inhibitors fail in the clinic. The study also raises questions about how to identify patients most likely to benefit—presumably those whose tumors show high ALDOA S39 phosphorylation, a biomarker that would itself need clinical validation. Still, the prospect of a targeted metabolic therapy for TNBC, a disease where targeted options are essentially nonexistent, is a compelling one.

The research was carried out by a consortium spanning several Chinese institutions, including the Beijing Institute of Lifeomics, the Academy of Military Medical Sciences, Renmin Hospital of Wuhan University, and collaborating universities, with corresponding authors Qinong Ye and Ping Xu coordinating the effort. The work was supported by national research programs in China, including the National Natural Science Foundation of China and the CAMS Innovation Fund for Medical Sciences. As the field of cancer metabolism continues to mature, this study stands as a demonstration that the phosphoproteome—the layer of cellular regulation sitting between genes and metabolism—can yield actionable drug targets for the cancers that need them most. For patients with triple-negative breast cancer, whose treatment options have barely expanded in decades, the MINK1–ALDOA axis now represents one of the most concrete and chemically tractable leads to emerge in years.